Patents by Inventor Paul Greenspan
Paul Greenspan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11968299Abstract: Certain aspects relate to encryption systems and methods for medical devices. A medical device can include a connectivity module for establishing a communication channel with a cloud system. After obtaining a test result, the device can generate an unencrypted data block comprising a device identifier and an encrypted data block comprising a serial number of the device and the test result using an encryption key associated with the device identifier. The device can securely send the test result to the cloud system by transmitting the unencrypted data block and the encrypted data block to the cloud system via the communication channel.Type: GrantFiled: November 28, 2022Date of Patent: April 23, 2024Assignee: BECTON, DICKINSON AND COMPANYInventors: Strett Roger Nicolson, Larry Greenspan, Michael Fenske, Paul Fieni, Mark Larsen
-
Patent number: 11542293Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 9, 2018Date of Patent: January 3, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Stepan Vyskocil, Jeffrey Ciavarri, Courtney Cullis, Dylan Bradley England, Alexandra E. Gould, Paul Greenspan, Yongbo Hu, Steven Langston, Gang Li, Hirotake Mizutani, Masanori Okaniwa
-
Publication number: 20210171565Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 9, 2018Publication date: June 10, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Stepan VYSKOCIL, Jeffrey CIAVARRI, Courtney CULLIS, Dylan Bradley ENGLAND, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Steven LANGSTON, Gang LI, Hirotake MIZUTANI, Masanori OKANIWA
-
Publication number: 20210015915Abstract: The present disclosure provides novel compounds of Formula (I) below. Compounds of the disclosure act as STING modulators/agonists. The present disclosure further relates to methods of synthesis of compounds of Formula (I) and methods of using of compounds of Formula (I) for the prophylaxis or treatment of cancer and other STING-related diseases. The compounds have the structure represented by Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 22, 2019Publication date: January 21, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Jeffrey CIAVARRI, Dylan Bradley ENGLAND, Kenneth M. GIGSTAD, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Shi-Chung HUANG, Steven Paul LANGSTON, Hirotake MIZUTANI, Zhan SHI, Stepan VYSKOCIL, He XU
-
Patent number: 8440664Abstract: This invention provides compounds of formula I: wherein R1, R2, CY, Y1, Y2, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.Type: GrantFiled: April 18, 2012Date of Patent: May 14, 2013Assignee: Millennium Pharmaceuticals, Inc.Inventors: David P. Cardin, Jeffrey Gaulin, Paul Greenspan, Christelle C. Renou, Stepan Vyskocil, Tianlin Xu
-
Publication number: 20120202812Abstract: This invention provides compounds of formula I: wherein R1, R2, CY, Y1, Y2, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.Type: ApplicationFiled: April 18, 2012Publication date: August 9, 2012Applicant: Millennium Pharmaceuticals, Inc.Inventors: David P. Cardin, Paul Greenspan, Stepan Vyskocil, Jeffrey Gaulin, Tianlin Xu, Christelle C. Renou
-
Patent number: 8183240Abstract: This invention provides compounds of formula I: wherein R1, R2, CY, Y1, Y2, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.Type: GrantFiled: June 17, 2009Date of Patent: May 22, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventors: David P. Cardin, Paul Greenspan, Stepan Vyskocil, Jeffrey Gaulin, Tianlin Xu, Christelle C. Renou
-
Publication number: 20100075951Abstract: This invention provides compounds of formula I: wherein R1, R2, CY, Y1, Y2, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.Type: ApplicationFiled: June 17, 2009Publication date: March 25, 2010Applicant: Millennium Pharmaceuticals, Inc.Inventors: David P. Cardin, Paul Greenspan, Stepan Vyskocil, Jeffrey Gaulin, Tianlin Xu, Christelle C. Renou
-
Publication number: 20080064729Abstract: The present invention provides novel phenethylamide compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: September 5, 2007Publication date: March 13, 2008Applicant: Millennium Pharmaceuticals, Inc.Inventors: Alexandra Gould, Paul Greenspan, Tricia Vos
-
Publication number: 20080027060Abstract: N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.Type: ApplicationFiled: August 7, 2007Publication date: January 31, 2008Inventors: Eva Altmann, Claudia Betschart, Keigo Gohda, Miyuki Horiuchi, Rene Lattmann, Martin Missbach, Junichi Sakaki, Michihiro Takai, Naoki Teno, Scott Cowen, Paul Greenspan, Leslie McQuire, Ruben Tommasi, John van Duzer
-
Publication number: 20070149533Abstract: The present invention provides novel bicyclic compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: December 7, 2006Publication date: June 28, 2007Applicant: Millennium Pharmaceuticals, Inc.Inventors: Emily Calderwood, Matthew Duffey, Alexandra Gould, Paul Greenspan, Bheemashankar Kulkarni, Matthew LaMarche, Robyn Rowland, Ming Tregay, Tricia Vos
-
Publication number: 20060160803Abstract: The present invention provides novel cinnamide compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: January 12, 2006Publication date: July 20, 2006Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth Adams, Emily Calderwood, Alexandra Gould, Paul Greenspan, Matthew LaMarche, Yuan Tian, Tricia Vos
-
Publication number: 20060035920Abstract: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.Type: ApplicationFiled: May 27, 2005Publication date: February 16, 2006Applicant: Millennium Pharmaceuticals, Inc.Inventors: Robert Boyle, Hassan Imogai, Michael Cherry, Alfred Humphries, Eva Navarro, David Owen, Natalie Dales, Matthew LaMarche, Courtney Cullis, Alexandra Gould, Paul Greenspan